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for Acute Myocardial Infarction
Is It Time for Another Clinical Trial?*Michael Ragosta, MDI n the current era of translational researchand evidence-based medicine, the publisheddata abounds with examples of promising ther-
apeutic strategies on the basis of brilliant theories
that succeed in the laboratory and in pilot studies
but fail in large-scale clinical trials. This has been
particularly true for adjunctive therapies designed
to reduce infarction in acute myocardial infarction
(MI). Over the past several decades, numerous clever
ideas have been proposed and tested. They succeeded
primarily in enhancing the academic careers of basic
scientists and cardiologists rather than the outcomes
of patients with MI. Strategies such as therapeutic
hypothermia, hyperbaric oxygen, stem cell injection,
distal protection devices, aspiration thrombectomy,
prophylactic intra-aortic balloon pumps, nitrates,
magnesium, pexelizumab (an anti-C5 complement
inhibitor), glucose/insulin/potassium infusion, and
other drugs have been studied as methods to reduce
infarction size or no-reﬂow. They were all on the
basis of sound physiological principles and promising
preliminary data, yet the expensive clinical trials
that followed did not ﬁnd clinical beneﬁt.
In theory, adenosine is one of the most promising
of these adjuncts. Several biological properties of
adenosine could prove beneﬁcial in patients with
acute MI such as augmentation and preservation of
microvascular ﬂow, inhibition of oxidative stress,
and inhibition of neutrophil-mediated reperfusion*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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disclose.injury (1). Animal models demonstrated reductions
in infarct size with adenosine, and small pilot studies
in humans showed promising results (1); however,
randomized clinical trials were mostly unsupportive.
In a trial of 236 patients within 6 h of MI treated with
lysis and randomized to a 3-h intravenous in-
fusion of 70 mg/kg/min of adenosine versus placebo
(AMISTAD [Acute Myocardial Infarction STudy of
ADenosine]), only the subgroup with anterior MI had
a reduction in infarct size compared with placebo (2).
AMISTAD II, a larger trial enrolling >2,000 patients
within 6 h of an anterior MI randomized to a 3-h
infusion of either low-dose (50 mg/kg/min) or high-
dose (70 mg/kg/min) adenosine or placebo, found no
difference in the primary endpoint of the study (new
heart failure or death within 6 months). A substudy
consisting of 243 patients designed to measure
infarct size observed no effect on infarct size in the
pooled adenosine groups; however, the high-dose
adenosine group had a signiﬁcant reduction in
infarct size versus placebo (3). Post-hoc analysis of
AMISTAD II observed improved outcomes in the sub-
set of patients undergoing reperfusion within the
ﬁrst 3 h of infarction (4). Other randomized clinical
trials using an intracoronary bolus of adenosine found
no beneﬁt (5,6). Thus, despite some “positive” ﬁnd-
ings, these clinical trials were essentially negative.
Adenosine is not used routinely for this purpose nor
is it recommended by current practice guidelines.
So why not abandon adenosine to the trash heap of
other good ideas that failed in clinical trials? The
answer to this question is complex, and many critics
consider the studies ﬂawed and the question
of adenosine’s beneﬁt in MI unresolved. Studies
designed to test whether a drug reduces reperfu-
sion injury and infarction size must consider many
variables. With such a very short half-life, the optimal
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2001dose, rate, duration, and route of adenosine admin-
istration are critical to get right. In addition, it is
important to deliver the drug at the optimal time
relative to the onset of infarction and reperfusion. It
is very possible that the existing clinical trials simply
got these parts wrong.
To add further complexity, the optimal window
during which a therapy may reduce reperfusion
injury and limit infarct size is likely very small. If
reperfusion is accomplished very early, say within
the ﬁrst hour or 2 of symptom onset, the area at
risk is mostly salvaged and the resulting infarction
and area at risk of reperfusion injury will likely be
very small. In such cases, a drug cannot be ex-
pected to show an improvement. Alternatively, if
reperfusion is delayed, say 6 to 8 h after symptom
onset, then the risk area is mostly infarcted. In such
cases, there will be little additional injury from
reperfusion and subsequently little beneﬁt from
agents that reduce reperfusion injury. Thus, agents
such as adenosine may only prove effective during
a very narrow time frame of only a few hours after
symptom onset.SEE PAGE 1990In this issue of JACC: Cardiovascular Interventions,
Yetgin et al. (7) persevered in the face of negative
trials and provide valuable insight into the role of
adenosine in limiting infarct size. Their study design
differed importantly from other work. They measured
the size of infarction and no-reﬂow in pigs subject to
45 min of coronary occlusion followed by 2 h of
reperfusion and compared the effect of 2 strategies of
adenosine with control subjects: an intracoronary
bolus of 3 mg adenosine administered over 1 min and
a 2-h intracoronary infusion of 50 mg/kg/min of
adenosine. The intracoronary bolus of adenosine had
no effect. There was no increase in blood ﬂow
(beyond the expected reactive hyperemia caused by
the infarction) and no reduction in infarction size, no-
reﬂow area, or attenuation of neutrophil inﬂux. In
contrast, intracoronary infusion of high-dose adeno-
sine increased blood ﬂow and caused an absolute 13%
reduction of infarct size and a 23% reduction in no-
reﬂow along with a nonsigniﬁcant trend toward
reduced neutrophil inﬁltration into the no-reﬂow
area. They concluded that only high-dose, pro-
longed, intracoronary administration of adenosine iseffective at reducing infarct size and no-reﬂow and
that adenosine as an adjunctive therapy should be
reconsidered.
Is it time then for another expensive trial? I believe
that this would be very challenging and require
extensive additional work to justify. The interesting
work by Yetgin et al. (7) created more questions
than answers. What is the optimal adenosine dose?
Instead of using the same dose for all, should the
dose be on the basis of the amount of adenosine
needed to achieve a certain blood ﬂow? Should we
use a Doppler FloWire to dose adenosine and, if so,
what is the optimal blood ﬂow needed for beneﬁt? Is
a 3- to 4-fold increase needed or is 2-fold adequate? Is
even higher better? For what duration should the
infusion be administered? Is 2 h necessary or is 1 h
enough? Clinicians will be faced with logistic prob-
lems to accomplish a prolonged intracoronary infu-
sion. Infusion through the guide catheter is
problematic as there is the potential to dislodge the
catheter during a prolonged infusion or there may be
reﬂux of drug into the aorta or noninfarct vessel
during infusion, thus diminishing the amount of drug
entering the infarct-related artery. This can be over-
come by positioning a microcatheter, allowing se-
lective infusion into the infarct-related artery, but
there may be additional risk during a prolonged
infusion. Prolonged infusion will also occupy the
cardiac catheterization laboratory for many hours; it
is unlikely that it will be safe to do this outside of the
lab for fear of catheter dislodgment or vessel injury.
Finally, the timing of adenosine administration rela-
tive to symptom onset and reperfusion remains to be
determined. As alluded to earlier, there may be only a
very narrow window of beneﬁt limited to patients
undergoing successful reperfusion 2 to 6 h after
symptom onset, but this needs additional careful
study. So, although I applaud the perseverance and
excellent work of Yetgin et al. (7), I doubt that
intracoronary adenosine will become routine therapy
after successful reperfusion therapy during acute MI
any time soon.
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